Health & Biotech
‘Tide is turning for the healthcare sector’ – ASX biotechs making strong gains in 2024 Part 3
Health & Biotech
CRITERION: Are profits on the horizon for the ASX’s aged care orphan?
Health & Biotech
Dr Boreham’s Crucible: Vitura Health is the tall poppy in a paddock of weed
Health & Biotech
‘Tide is turning for the healthcare sector’ – ASX biotechs making strong gains in 2024 Part 2
Health & Biotech
PharmAust files groundbreaking MND/ALS clinical data with the FDA
Health & Biotech
International cardiometabolic expert to join Race Oncology’s scientific advisory board
Health & Biotech
EZZ products to gain exposure to increasing Chinese tourist numbers at Auckland airport under duty-free deal
Health & Biotech
‘Tide is turning for the healthcare sector’ – ASX biotechs making strong gains in 2024 Part 1
Health & Biotech
Neurotech extends clinical trials for the $US2bn Rett Syndrome market
Health & Biotech
Dimerix completes ‘highly strategic’ $20m cap raise to advance ACTION3 Phase 3 trial
Health & Biotech
‘A key milestone’: Dimerix ACTION3 Phase 3 trial interim results meet endpoint
Health & Biotech
ASX Health Stocks: Dimerix ACTION3 Phase 3 interim trial results are out… and they’re good
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.